Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31615Editorial articleПередовая статьяReview ArticleThyroid dysfunction and the hemostatic systemНарушения функции щитовидной железы и система гемостазаPlatonovaN MПлатоноваН Мdoc-platonova@inbox.ruSviridonovaM AСвиридоноваМ АTroshinaE AТрошинаЕ АФГБУ "Эндокринологический научный центр" Минздрава России, Москва151020148610VOL 86, NO10 (2014)ТОМ 86, №10 (2014)929610042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31615

Whether there is a link between thyroid dysfunction and different impairments in the hemostatic system is discussed. The level of thyroid hormones is an essential factor that influences the coagulation system. Thyroid dysfunction affects the balance between coagulation and fibrinolysis, by increasing the risk of thrombosis and hemorrhage in hyperthyroidism. However, there is no consensus of opinion regarding the mechanisms of the described hemostatic changes in the literature.

Аннотация. Обсуждается вопрос взаимосвязи дисфункции щитовидной железы (ЩЖ) и различных нарушений в системе гемостаза. Уровень тиреоидных гормонов - существенный фактор, влияющий на свертывающую систему крови. Дисфункция ЩЖ влияет на баланс между коагуляцией и фибринолизом, увеличивая риск развития тромбозов при гипертиреозе и кровотечений при гипотиреозе. Однако в литературе нет единого мнения о механизмах описанных гемостатических изменений.

thyroidcoagulationfibrinolysishypothyroidismhyperthyroidismthrombosisbleedinghemostatic systemщитовидная железакоагуляцияфибринолизгипотиреозгипертиреозтромбозкровотечениесистема гемостазаShih C.H., Chen S.L., Yen C.C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 2004; 145: 2804-2814.Franklyn J.A., Sheppard M.C., Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294 (1): 71-80.Metso S., Jaatinen P., Huhtala H. et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrin Metab 2007; 92 (6): 2190-2196.Nyirenda M.J., Clark D.N., Finlayson A.R. et al. Thyroid disease and increased cardiovascular risk. Thyroid 2005; 15 (7): 718-725.Squizzato A., Gerdes V.E.A, Brandjes D.P.M. et al. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36: 2302-2310.Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol 2006; 64: 323-329.Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. New Engl J Med 2001; 344: 501-509.Физиология человека. Под ред. В.М. Покровского, В.Г. Коротько. Т. 1. М: Медицина 1997: 313-325.Торшин В.И., Власова В.М., Агаджанян Н.А. Основы физиологии человека. В учебнике для студентов вузов, обучающихся по медицинским и биологическим специальностям, 2-е изд., исправл. М: РУДН 2001: 154-165Bennett N.B., Ogston C.M., McAndrew G.M. The thyroid and fibrinolysis. Br Med J 1967; 4: 147-148.Squizzato A., Gerdes V.E., Brandjes D.P. et al. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36 (10): 2302-2310.Marongiu F., Conti M., Murtas M.L. et al. Anticardiolipin antibodies in Graves' disease: relationship with thrombin activity in vivo. Thromb Res 1991; 64 (6): 745-749.Lodha A., Haran M., Frankel R., Shani J. Thyrotoxicosis causing arterial and venous thrombosis. Am J Med Sci 2009; 338 (5): 428-437.Erem C., Ersoz H.Ö., Karti S.S. et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25 (4): 345-350.Lippi G., Franchini M., Targher G. et al. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombolys 2009; 28 (3): 362-365.Burggraaf J., Lalezari S., Emeis J.J. et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazole. Thyroid 2001; 11 (2): 153-160.Soma M., Maeda Y., Matsuura R. et al. Study of serum thrombomodulin (TM) levels in patients with hyper- or hypothyroidism [in Japanese]. Rinsho Byori 1997; 45 (1): 77-81.Franchini M. Hemostasis and thyroid diseases revisited. J Endocrinol Invest 2004; 27 (9): 886-892.Rogers J.S., Shane S.R. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-449.Horne M.K. 3rd, Singh K.K., Rosenfeld K.G. et al. Is thyroid hormone suppression therapy prothrombotic. J Clin Endocrinol Metab 2004; 9: 4469-4473.Demir T., Akinci B., Comlekci A. et al. 2008 Levothyroxine suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol (Oxf) 2009; 71 (3): 446-450.Negrev N.N., Radev R.Z., Velikova M.S., Anogeianaki A. Effects of the hormones of the thyroid axis on the vitamin K-dependent plasma factors of blood coagulation (II, VII, IX and X). Int J Immunopathol Pharmacol 2008; 21: 221-226.Kellett H.A., Sawers J.S., Boulton F.E. et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58: 43-51.Sievert R., Goldstein M.L., Surks M.I. Graves' disease and autoimmune factor VIII deficiency. Thyroid 1996; 6: 245-247.Marongiu F., Cauli C., Mameli G. et al. Apathetic Graves' disease and acquired hemophilia due to factor VIIIc antibody. J Endocrinol Invest 2002; 25: 246-249.Dorr M., Robinson D.M., Wallaschofski H. et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91: 530-534.Coban E., Aydemir M., Yazicioglu G., Ozdogan M. Endothelial dysfunction in subjects with subclinical hyperthyroidism. J Endocrinol Invest 2006; 29: 197-200.Stuijver D.J., van Zaane B., Romualdi E. et al. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 2012; 108 (6): 1077-1088.Hofbauer L.C., Heufelder A.E. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997; 136: 1-7.Marqusee E., Mandel S.J. The blood in hypothyroidism, in Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, 8th edn., ed. by L.E. Braverman, R.D. Utiger. Lippincott Williams & Wilkins, Philadelphia 2000: 800-803.Egeberg B.O. Influence of thyroid function on blood clotting system. Scand J Clin Lab Invest 1963; 15: 1-7.Simone J.V., Abildgaard C.F., Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med 1965; 273: 1057-1061.Hume R. Fibrinolytic activity and thyroid function. Br Med J 1965; 1: 686-688.Rennie J.A., Bewsher P.D., Murchison L.E., Ogston D. Coagulation and fibrinolysis in thyroid disease. Acta Haematol 1978; 59: 171-177.Gullu S., Sav H., Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol 2005; 152: 355-361.Arnaout M.A., Awidi A.S., el-Najdawi A.M. et al. Arginine-vasopressin and endothelium-associated proteins in thyroid disease. Acta Endocrinol (Copenh) 1992; 126: 399-403.Marongiu F., Biondi G., Conti M. et al. Is a hypercoagulable state present in hypothyroidism. Thromb Haemost 1992; 67: 729.Chadarevian R., Bruckert E., Ankri A. et al. Relationship between thyroid hormones and plasma D-dimer levels. Thromb Haemost 1998; 79: 99-103.Chadarevian R., Bruckert E., Giral P., Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagul Fibrinolysis 1999; 10: 481-486.Yong P.H., Junit S.M., Harun F., Hashim O.H. Patients with congenital hypothyroidism demonstrate different altered expression of plasma fibrinogen and haptoglobin polypeptide chains. Clin Biochem 2006; 39: 126-132.Erem C., Kavgaci H., Ersöz H.O. et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 2003; 57: 78-81.Akinci B., Comlekci A., Yener S. et al. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J 2007; 54: 593-599.Verkleij C.J., Stuijver D.J., van Zaane B. et al. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Thromb Haemost 2013; 109 (2): 214-220.Erem C., Ucuncu O., Yilmaz M. et al. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism. Endocrine 2009; 35 (1): 75-80.Muller B., Tsakiris D.A., Roth C.B. et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001; 31: 131-137.Jayaprasad N., Francis J. Atrial fibrillation and hyperthyroidism. Indian Pacing Electrophysiol J 2005; 5: 305-311.Bar-Sela S., Ehrenfeld M., Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141: 1191-1192.Chadarevian R., Bruckert E., Leenhardt L. et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86: 732-737.Guldiken S., Demir M., Turgut B. et al. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocr J 2005; 52: 363-367.Jorde R., Figenschau Y., Hansen J.B. Haemostatic function in subjects with mild subclinical hypothyroidism. The Tromso study. Thromb Haemost 2006; 95: 750-751.